Abstract
Solid organ and hematopoietic stem cell transplant recipients are at high risk of contracting infectious diseases, including vaccine-preventable illnesses, in the post-transplant period. Given the high degree of immunosuppression immediately post-transplant, infection in the transplant patient results in higher morbidity and mortality than in the general population. Thus, it is the responsibility of the care team to ensure appropriate vaccines are given in an attempt to mitigate this risk. Timing of vaccination in the solid organ or hematopoietic stem cell transplant recipient is critical in order to strike a balance between providing protection against vaccine-preventable illnesses as early as possible, and vaccinating at a time when it is safe and the host’s immune response to vaccination will be adequate. This chapter will focus on providing a rationale for and summary of the specific recommendations pertaining to vaccination of both the solid organ and hematopoietic stem cell transplant recipient.
Similar content being viewed by others
References
Mawhinney H, Allen IV, Beare JM, et al. Dysgammaglobulinemia complicated by disseminated measles. Br Med J. 1971;2:380–1.
Mitus A, Holloway A, Evans AE, Enders JF. Attenuated measles vaccine in children with acute leukemia. Am J Dis Child. 1962;103:413–8.
Kobashigawa JA, Warner L, Stevenson BL, et al. Influenza vaccine does not cause rejection after cardiac transplantation. Transplant Proc. 1993;25:2738–9.
Kimball P, Verbeke S, Flattery M, Rhodes C, Tolman D. Influenza vaccination does not promote cellular or humoral activation among heart transplant recipients. Transplantation. 2000;69:2449–51.
Magnani G, Falchetti E, Pollini G, et al. Safety and efficacy of two types of influenza vaccination in heart transplant recipients: a prospective randomized controlled study. J Heart Lung Transplant. 2005;24:588–92.
Danziger-Isakov L, Kumar D. Vaccination of solid organ transplant candidates and recipients: guidelines from the American society of transplantation infectious diseases community of practice. Clin Transpl. 2019;33:e13563. https://doi.org/10.1111/ctr.13563.
Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009;15:1143–238.
Kumar D, Ferreria VH, Blumberg E, et al. A 5-year prospective multicenter evaluation of influenza infection in transplant recipients. Clin Infect Dis. 2018;67:1322–9.
Ljungman P, de la Camara R, Perez-Bercoff L, Infectious Diseases Working Party, European Group for Blood and Marrow Transplantation, Infectious Complications Subcommittee, Spanish Group of Hematopoietic Stem-Cell Transplantation, et al. Outcome of pandemic H1N1 infections in hematopoietic stem cell transplant recipients. Hematologica. 2011;96:1231–5.
Kmeid J, Vanichanan J, Shah DP, et al. Outcomes of influenza infections in hematopoietic stem cell transplant recipients: an application of an immunodeficiency scoring index. Biol Blood Marrow Transplant. 2016;22:542–8.
Reid G, Huprikar S, Patel G, et al. A multicenter evaluation of pandemic influenza A/H1N1 in hematopoietic stem cell transplant recipients. Transpl Infect Dis. 2013;15:487–92.
Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58:309–18.
Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9(Suppl 3):S1–S157.
Baluch A, Humar A, Eurich D, et al. Randomized controlled trial of high-dose intradermal versus standard-dose intramuscular influenza vaccine in organ transplant recipients. Am J Transplant. 2013;13:1026–33.
Mulley WR, Dendle C, Ling JEH, Knight SR. Does vaccination in solid-organ transplant recipients result in adverse immunologic sequelae? A systematic review and meta-analysis. J Heart Lung Transplant. 2018;37:844–52.
Kumar D, Blumberg EA, Danziger-Isakov L, et al. Influenza vaccination in the organ transplant recipient: review and summary recommendations. Am J Transplant. 2011;11:2020–30.
Arnou R, Eavis P, Pardo JR, Ambrozaitis A, Kazek MP, Weber F. Immunogenicity, large scale safety and lot consistency of an intra-dermal influenza vaccine in adults aged 18–60 years: randomized, controlled, phase III trial. Hum Vaccin. 2010;6:346–54.
Kumar D, Campbell P, Hoschler K, et al. Randomized controlled trial of adjuvanted versus nonadjuvanted influenza vaccine in kidney transplant recipients. Transplantation. 2016;100:662–9.
Cordero E, Roca-Oporto C, Bulnes-Ramos A, et al. Two doses of inactivated influenza vaccine improve immune response in solid organ transplant recipients: results of TRANSGRIPE 1-2, a randomized controlled clinical trial. Clin Infect Dis. 2017;64:829–38.
Natori Y, Shiotsuka M, Slomovic J, et al. A double-blind, randomized trial of high-dose vs standard-dose influenza vaccine in adult solid-organ transplant recipients. Clin Infect Dis. 2018;66:1698–704.
Cordonnier C, Einarsdottir S, Cesaro S, et al. Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European conference of infections in leukemia (ECIL-7). Lancet Infect Dis. 2019; https://doi.org/10.1016/S1472-3099(18)30600-5.
Issa NC, Marty FM, Gagne LS, et al. Seroprotective titers against 2009 H1N1 influenza A virus after vaccination in allogeneic hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2011;17:434–8.
Engelhard D, Nagler A, Hardan I, et al. Antibody response to a two-dose regimen of influenza vaccine in allogeneic T-cell depleted and autologous BMT recipients. Bone Marrow Transplant. 1993;11:1–5.
Natori Y, Humar A, Lipton J, et al. A pilot randomized trial of adjuvanted influenza vaccine in adult allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2017;52:1016–21.
Mohty B, Bel M, Vukicevic M, et al. Graft-versus-host disease is the major determinant of humoral responses to the AS03-adjuvanted influenza A/09/H1N1 vaccine in allogeneic hematopoietic stem cell transplant recipients. Haematologica. 2011;96:896–904.
Fukatsu Y, Nagata Y, Adachi M, Yagu T, Ono T. Serum IgM levels independently predict immune response to influenza vaccine in long-term survivors vaccinated at > 1 year after undergoing allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2017;105:638–45.
Karras NA, Weeres M, Sessions W, et al. A randomized trial of one versus two doses of influenza vaccine after allogeneic transplantation. Biol Blood Marrow Transplant. 2013;19:109–16.
Pauksen K, Linde A, Hammarstrom V, et al. Granulocyte-macrophage colony-stimulating factor as immunomodulating factor together with influenza vaccination in stem cell transplant recipients. Clin Infect Dis. 2000;30:342–8.
Ambati A, Boas LS, Ljungman P, et al. Evaluation of pretransplant influenza vaccination in hematopoietic SCT: a randomized prospective study. Bone Marrow Transplant. 2015;50:858–64.
Halasa NM, Savani BN, Asokan I, et al. Randomized double-blind study of the safety and immunogenicity of standard-dose trivalent inactivated influenza vaccine versus high-dose trivalent inactivated influenza vaccine in hematopoietic stem cell transplant patients. Biol Blood Marrow Transplant. 2016;22:528–35.
Kumar D, Humar A, Plevneshi A, et al. Invasive pneumococcal disease in solid organ transplant recipients – 10-year prospective population surveillance. Am J Transplant. 2007;7:1209–14.
Kulkarni S, Powles R, Treleaven J, et al. Chronic graft versus host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants. Blood. 2000;95:3683–6.
Dendle C, Stuart RL, Mulley WR, Holdsworth SR, et al. Pneumococcal vaccination in adult solid organ transplant recipients: a review of current evidence. Vaccine. 2018;36:6253–61.
Kumar D, Rotstein C, Miyata G, Arlen D, Humar A. Randomized, double-blinded, controlled trial of pneumococcal vaccination in renal transplant recipients. J Infect Dis. 2003;187:1639–45.
Kumar D, Welsh B, Siegal D, Chen MH, Humar A. Immunogenicity of pneumococcal vaccine in renal transplant recipients – three year follow-up of a randomized trial. Am J Transplant. 2007;7:633–8.
Dendle C, Stuart RL, Polkinghorne KR, et al. Seroresponses and safety of 13-valent pneumococcal conjugate vaccination in kidney transplant recipients. Transpl Infect Dis. 2018;20:e12866. https://doi.org/10.1111/tid.12866.
Kumar D, Chen MH, Wong G, et al. A randomized, double-blind, placebo-controlled trial to evaluate the prime-boost strategy for pneumococcal vaccination in adult liver transplant recipients. Clin Infect Dis. 2008;47:885–92.
Tobudic S, Plunger V, Sunder-Plassmann G, Riegersperger M, Burgmann H. Randomized, single blind, controlled trial to evaluate the prime-boost strategy for pneumococcal vaccination in renal transplant recipients. PLoS One. 2012;7:e46133. https://doi.org/10.1371/journalpone.0046133.
Barton M, Wasfy S, Dipchand AI, et al. Seven-valent pneumococcal conjugate vaccine in pediatric solid organ transplant recipients. Pediatr Infect Dis J. 2009;28:688–92.
Kobayashi M, Bennet N, Gierke R, et al. Intervals between PCV13 and PPSV23 vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2015;64:944–7.
Kumar D, Humar A, Plevneshi A, et al. Invasive pneumococcal disease in adult hematopoietic stem cell transplant recipients: a decade of prospective population-based surveillance. Bone Marrow Transplant. 2008;41:743–7.
Engelhard D, Cordonnier C, Shaw PJ, et al. Early and late invasive pneumococcal infection following stem cell transplantation: a European Bone Marrow Transplantation survey. Br J Haematol. 2002;117:444–50.
Debbache K, Varon E, Hicheri Y, et al. The epidemiology of invasive Streptococcus pneumoniae infections in onco-haematology and haematopoietic stem cell transplant patients in France. Are the serotypes covered by the available anti-pneumococcal vaccines? Clin Microbiol Infect. 2009;15:865–8.
Guinan EC, Molrine DC, Antin JH, et al. Polysaccharide conjugate vaccine responses in bone marrow transplant patients. Transplantation. 1994;57:677–84.
Kumar D, Chen MH, Welsh B, et al. A randomized, double-blind trial of pneumococcal vaccination in adult allogeneic stem cell transplant donors and recipients. Clin Infect Dis. 2007;45:1576–82.
Cordonnier C, Labopin M, Chesnel V, et al. Randomized study of early versus late immunization with pneumococcal conjugate vaccine after allogeneic stem cell transplantation. Clin Infect Dis. 2009;48:1392–401.
Cordonnier C, Labopin M, Chesnel V, et al. Immune response to the 23-valent polysaccharide pneumococcal vaccine after the 7-valent conjugate vaccine in allogeneic stem cell transplant recipients: results from the EBMT IDWP01 trial. Vaccine. 2010;28:2730–4.
Cordonnier C, Ljungman P, Juergens C, et al. Immunogenicity, safety, and tolerability of 13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine in recipients of allogeneic hematopoietic stem cell transplant aged ≥ 2 years: an open-label study. Clin Infect Dis. 2015;61:313–23.
CDC. Meningococcal disease. Atlanta: US Department of Health and Human Services. CDC; 2017. https://www.cdc.gov/meningococcal/surveillance/index.html
Kotton CN, Hibberd PL, The AST Infectious Diseases Community of Practice. Travel medicine and transplant tourism in solid organ transplantation. Am J Transplant. 2013;13:337–47.
Food and Drug Administration. Alexion briefing information for the November 18, 2014, meeting of the Drug Safety and Risk Management Advisory Committee. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DrugSDrugSafetyandRiskManagementAdvisoryComm/ucm423029.htm
CDC. Meningococcal ACIP recommendations. Atlanta: US Department of Health and Human Services. CDC; 2017. https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/mening.html
Struijk GH, Bouts AHM, Rijkers GT, Kuin EAC, ten Berge IJM, Bemelman FJ. Meningococcal sepsis complicating eculizumab treatment despite prior vaccination. Am J Transplant. 2013;13:819–20.
Wyplosz B, Derradji O, Hong E, et al. Low immunogenicity of quadrivalent meningococcal vaccines in solid organ transplant recipients. Transpl Infect Dis. 2015;17:322–7.
Mahler MB, Taur Y, Jean R, Kernan NA, Prockop SE, Small TN. Safety and immunogenicity of the tetravalent protein-conjugated meningococcal vaccine (MCV4) in recipients of related and unrelated allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012;18:141–55.
Food and Drug Administration. Product approval information: package insert. Heplisav-B. Silver Spring: US Department of Health and Human Services, Food and Drug Administration; 2018. https://www.fda.gov/BiologicsBloodVaccines/ApprovedProducts/ucm584752.htm
Huprikar S, Danziger-Isakov L, Ahn J, et al. Solid organ transplantation from hepatitis B virus-positive donors: consensus guidelines for recipient management. Am J Transplant. 2015;15:1162–72.
Skagen CL, Jou JH, Said A. Risk of de novo hepatitis in liver recipients from hepatitis-B core antibody-positive grafts – a systematic analysis. Clin Transpl. 2011;25:E243–9.
Lefebure AF, Verpooten GA, Couttenye MM, De Broe ME. Immunogenicity of a recombinant DNA hepatitis B vaccine in renal transplant recipients. Vaccine. 1993;11:397–9.
Loinaz C, de Juanes JR, Gonzalez EM, et al. Hepatitis B vaccination results in 140 liver transplant recipients. Hepato-Gastroenterology. 1997;44:235–8.
Stevens CE, Alter HJ, Taylor PE, Zang EA, Harley EJ, Szmuness W. Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy. N Engl J Med. 1984;311:496–501.
Horlander JC, Boyle N, Manam R, et al. Vaccination against hepatitis B in patients with chronic liver disease awaiting liver transplantation. Am J Med Sci. 1999;318:304–7.
Mallet V, van Bommel F, Doerig C, et al. Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5). Lancet Infect Dis. 2016;16:606–17.
Shouval D, Ilan Y. Transplantation of hepatitis B immune lymphocytes as means for adoptive transfer of immunity to hepatitis B virus. J Hepatol. 1995;23:98–101.
Jaffe D, Papadopoulos EB, Young JW, et al. Immunogenicity of recombinant hepatitis B vaccine (rHBV) in recipients of unrelated or related allogeneic hematopoietic cell (HC) transplants. Blood. 2006;108:2470–5.
Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2006;55:1–23.
Arslan M, Wiesner RH, Poterucha JJ, Zein NN. Safety and efficacy of hepatitis A vaccination in liver transplant recipients. Transplantation. 2001;72:272–6.
Arslan M, Wiesner RH, Poterucha JJ, Gross JB Jr, Zein NN. Hepatitis A antibodies in liver transplant recipients: evidence for loss of immunity posttransplantation. Liver Transpl. 2000;6:191–5.
Madeleine MM, Finch JL, Lynch CF, Goodman MT, Engels EA. HPV-related cancers after solid organ transplantation in the US. Am J Transplant. 2013;13:3202–9. https://doi.org/10.1111/ajt.12472.
Kumar D, Unger ER, Paonicker G, Medvedev P, Wilson L, Humar A. Immunogenicity of quadrivalent human papillomavirus vaccine in organ transplant recipients. Am J Transplant. 2013;13:2411–7. https://doi.org/10.1111/ajt.12329.
Munoz N, Manalastas R Jr, Pitisuttithum P, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial. Lancet. 2009;373:1949–57.
Gomez-Lobo V, Whyte T, Kaufman S, Torres C, Moudgil A. Immunogenicity of a prophylactic quadrivalent human papillomavirus LI virus-like particle vaccine in male and female adolescent transplant recipients. Pediatr Transplant. 2014;18:310–5.
Nelson DR, Neu AM, Abraham A, Amaral S, Batisky D, Fadrowski JJ. Immunogenicity of human papillomavirus recombinant vaccine in children with CKD. Clin J Am Soc Nephrol. 2016;11:776–84.
Petrosky E, Bocchini JA Jr, Hariri S, et al. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2015;64:300–4.
Savani BN, Stratton P, Shenoy A, Kozanas E, Goodman S, Barrett AJ. Increased risk of cervical dysplasia in long-term survivors of allogeneic stem cell transplantation – implications for screening and HPV vaccination. Biol Blood Marrow Transplant. 2008;14:1072–5. https://doi.org/10.1016/j.bbmt.2008.07.005.
Lawrence R, Gershon AA, Holzman R, Steinberg SP. The risk of zoster after varicella vaccination in children with leukemia. N Engl J Med. 1988;318:543–8.
Heininger U, Seward JF. Varicella. Lancet. 2006;368:1365–76.
Rawson H, Crampin A, Noah N. Deaths from chickenpox in England and Wales 1997–7: analysis of routine mortality data. BMJ. 2001;323:1091–3.
Posfay-Barbe KM, Pittet LF, Sottas C, et al. Varicella-zoster immunization in pediatric liver transplant recipients: safe and immunogenic. Am J Transplant. 2012;12:2974–85.
Weinberg A, Horslen SP, Kaufman SS, et al. Safety and immunogenicity of varicella-zoster virus vaccine in pediatric liver and intestine transplant recipients. Am J Transplant. 2006;6:565–8.
Kraft JN, Shaw JC. Varicella infection caused by Oka strain vaccine in a heart transplant recipient. Arch Dermatol. 2006;142:943–5.
Levitsky J, Te HS, Faust TW, Cohen SM. Varicella infection following varicella vaccination in a liver transplant recipient. Am J Transplant. 2002;2:880–2.
Locksley RM, Flournoy N, Sullivan KM, Meyers JD. Infection with varicella-zoster virus after marrow transplantation. J Infect Dis. 1985;152:1172–81.
Sasadeusz J, Prince HM, Schwarer A, et al. Immunogenicity and safety of a two-dose live attenuated varicella vaccine given to adults following autologous hematopoietic stem cell transplantation. Transpl Infect Dis. 2014;16:1024–31. https://doi.org/10.1111/tid.12295.
Ezeanolue E, Harriman K, Hunter P, Kroger A, Pellegrini C. General best practice guidelines for immunization. Best practices guidance of the Advisory Committee on Immunization Practices (ACIP). http://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf
Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352:2271–84.
Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372:2087–96.
Lal H, Cunningham AL, Kovac M, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375:1019–32.
Gourishankar S, McDermind JC, Jhangri GS, Preiksaitis JK. Herpes zoster infection following solid organ transplantation: incidence, risk factors, and outcomes in the current immunosuppressive era. Am J Transplant. 2004;4:108–15.
Manuel O, Kumar D, Singer LG, Cobos I, Humar A. Incidence and clinical characteristics of herpes zoster after lung transplantation. J Heart Lung Transpant. 2008;27:11–6.
Kho M, Weimar W, Bovee D, Boer-Verschragen M, van der Eijk A, Van Besouw N. Vaccination to prevent the high herpes zoster incidence after renal transplantation [abstract]. Am J Transplant. 2015;15 (Suppl 3). https://atcmeetingabstracts.com/abstract/vaccination-to-prevent-the-high-herpes-zoster-incidence-after-renal-transplantation/
Hamaguchi Y, Mori A, Uemura T, et al. Incidence and risk factors for herpes zoster in patients undergoing liver transplantation. Transpl Infect Dis. 2015;17:671–8.
Koo S, Gagne LS, Lee P, et al. Incidence and risk factors for herpes zoster following heart transplantation. Transpl Infect Dis. 2014;26:17–25.
Miller G, Schaefer H, Yoder S, et al. A randomized, placebo-controlled phase I trial of live, attenuated herpes zoster vaccine in subjects with end-stage renal disease immunized prior to renal transplantation. Transpl Infect Dis. 2018;20:e12874. https://doi.org/10.1111/tid.12874.
Vink P, Ramon Torrell JM, Sanchez Fructuoso A, et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in chronically immunosuppressed adults following renal transplant: a phase III, randomized clinical trial. Clin Infect Dis. 2019. pii: ciz177. https://doi.org/10.1093/cid/ciz177.
Issa NC, Marty FM, Leblebjian H, et al. Live attenuated varicella-zoster vaccine in hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2014;20:279–87.
Stadtmauer EA, Sullivan KM, Marty FM, et al. A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients. Blood. 2014;124:2921–9.
Winston DJ, Mullane KM, Cornely OA, et al. Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391:2116–27.
Rand EB, McCarthy CA, Whitington PF. Measles vaccination after orthotopic liver transplantation. J Pediatr. 1993;123:87–9.
Kano H, Mizuta K, Sakakihara Y, et al. Efficacy and safety of immunization for pre- and post-liver transplant children. Transplantation. 2002;74:543–50.
Shinjoh M, Miyairi I, Hoshino K, Takahashi T, Nakayama T. Effective and safe immunizations with live-attenuated vaccines for children after living donor liver transplantation. Vaccine. 2008;26:6859–63.
Pittet LF, Verolet CM, McLin VA, et al. Multimodal safety assessment of measles-mumps-rubella vaccination after pediatric liver transplantation. Am J Transplant. 2019;19:844–54.
Ljungman P, Fridell E, Lonngvist B, et al. Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps, and rubella vaccine. J Infect Dis. 1989;159:610–5.
Machado CM, Goncalves FB, Pannuti CS, Dulley FL, de Souza VA. Measles in bone marrow transplant recipients during an outbreak in Sao Paulo, Brazil. Blood. 2002;99:83–7.
Machado CM, de Souza VA, Sumita LM, da Rocha IF, Dulley FL, Pannuti CS. Early measles vaccination in bone marrow transplant recipients. Bone Marrow Transplant. 2005;35:787–91.
Sicre de Fontbrune F, Arnaud C, Cheminant M, et al. Immunogenicity and safety of yellow fever vaccine in allogeneic hematopoietic stem cell transplant recipients after withdrawal of immunosuppressive therapy. J Infect Dis. 2018;217:494–7.
Azevedo LS, Lasmar EP, Contieri FL, et al. Yellow fever vaccination in organ transplanted patients: is it safe? A multicenter study. Transpl Infect Dis. 2012;14:237–41.
Grohskopf LA, Sokolow LZ, Broder KR, Walter EB, Fry AM, Jernigan DB. Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices – United States, 2018–19 influenza season. MMWR Recomm Rep. 2018;67:1–20.
Prevots DR, Burr RK, Sutter RW, Murphy TV. Poliomyelitis prevention in the United States. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2000;49:1–22.
Food and Drug Administration. Product approval information-licensing action, package insert: Rotateq (Rotavirus Vaccine, Live, Oral Pentavalent), Merck. Rockville: US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; 2006.
Food and Drug Administration. Rotarix clinical review. Rockville: US Department of Health and Human Services, Food and Drug Administration; 2008. http://www.fda.gov/cber/products/rotarix/rotarix031008.rev.pdf
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this entry
Cite this entry
Jain, S.R., Kumar, D. (2020). Vaccination Strategies in Solid Organ and Stem Cell Transplant. In: Morris, M., Kotton, C., Wolfe, C. (eds) Emerging Transplant Infections. Springer, Cham. https://doi.org/10.1007/978-3-030-01751-4_11-1
Download citation
DOI: https://doi.org/10.1007/978-3-030-01751-4_11-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-01751-4
Online ISBN: 978-3-030-01751-4
eBook Packages: Springer Reference MedicineReference Module Medicine